Non-Interventional Study on the Side Effects of Empagliflozin Compared with DPP-4 Inhibitors in Patients with Type 2 Diabetes in New Zealand

Study identification

• EU PAS number:
  EUPAS106713
• Study ID:
  106714
• Official title and acronym:
  Non-Interventional Study on the Side Effects of Empagliflozin Compared with DPP-4 Inhibitors in Patients with Type 2 Diabetes in New Zealand
• DARWIN EU® study:
  No
• Study countries:
  New Zealand
• Study description:
  The purpose of this study is to compare the prevalence of the side effects of SGLT2 inhibitors in a large population of new users with type 2 diabetes (T2DM) in New Zealand compared to propensity score (PS) matched patients with T2DM initiating vildagliptin within the year 2021.
• Study status:
  Ongoing

Research institutions and networks

Institutions

University of Auckland

Study timelines

Date when funding contract was signed

Planned:01/04/2022

Study start date

Planned:15/03/2023

Actual:04/07/2023

Date of final study report

Planned:31/03/2024

Sources of funding

Other

More details on funding

The University of Auckland

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable